News tagged with paclitaxel

Related topics: breast cancer , cancer , cancer cells , chemotherapy , ovarian cancer

Results of the ROTAXUS trial reported at TCT 2011

A clinical trial testing the efficacy of rotational atherectomy (or rotablation, a process of drilling through plaque deposits) prior to implantation of a drug-eluting stent found that the process was not superior to standard ...

Nov 11, 2011
popularity 0 comments 0

Gene fault could predict ovarian cancer drug success

Faults in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to research at Newcastle University.

Jun 06, 2011
popularity 0 comments 0

New hope for taming triple-negative breast cancer

Disease-free survival is short-lived for women with triple-negative breast cancer—a form of the disease that doesn't respond to hormone drugs and becomes resistant to chemotherapy. Thankfully, a promising ...

Oct 02, 2012
popularity 0 comments 0

Drug-Eluting stents reduce risk of thrombosis

(HealthDay) -- Cobalt-chromium everolimus eluting stents (CoCr-EES) are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting ...

Mar 23, 2012
popularity 0 comments 0

Paclitaxel

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a U.S. National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. When it was developed commercially by Bristol-Myers Squibb (BMS) the generic name was changed to paclitaxel and the BMS compound is sold under the trademark TAXOL. In this formulation, paclitaxel is dissolved in Cremophor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane.

Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is also used for the prevention of restenosis.

Paclitaxel stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division. Together with docetaxel, it forms the drug category of the taxanes. It was the subject of a notable total synthesis by Robert A. Holton.

While offering substantial improvement in patient care, paclitaxel has been a relatively controversial drug. There was originally concern because of the environmental impact of its original sourcing, no longer used, from the Pacific yew. In addition, the assignment of rights, and even the name itself, to Bristol-Myers Squibb were the subject of public debate and Congressional hearings.

This text uses material from Wikipedia licensed under CC BY-SA